Grégory Piot

Learn More
Despite many advantages that could be gained through belonging to enterprise networks, only a few networks continue running businesses after the governments stop their funding. One of the reasons is the lack of a model that evaluates the benefits from the firm's point of view. The objective of this work is to develop a model that estimates the benefits in(More)
In order to define prognostic factors for advanced stage of nonseminomatous germ cell tumors (NSGCT) of the testis, the authors reviewed 84 patients treated from 1978 through 1985. The survival rate was 51% at 3 years. Patients with elevated seric levels of human chorionic gonadotropin (HCG) and/or alpha-fetoprotein (AFP), or the presence of an abdominal(More)
Nowadays, the advantages of virtual enterprises and collaborative networks are well known by scientists and professional communities. Despite the advantages, only a few networks continue running businesses after stopping the governmental subsides. One of the reasons is the lack of a model that evaluates the benefit from the firm's point of view. The(More)
One hundred fifty-three adult patients with metastatic renal carcinoma were treated over a 12-year period. Five successive chemotherapeutic protocols were used: vincristine or teniposide plus CCNU, elliptinium weekly or monthly, ifosfamide, and lastly, a multidrug regimen with adriamycin, vindesine, cyclophosphamide, cisplatinum, and dacarbazine. Results(More)
Thirty-eight patients with advanced colorectal adenocarcinoma were entered on a phase II trial of 5-fluorouracil (5-FU) in continuous infusion, using a portable pump. Half of the patients had been pretreated (n = 19) and 16 of them had received intravenous bolus 5-FU alone or in combination. At the first cycle patients received continuous intravenous 5-FU(More)
From October 1985 to December 1986, 25 patients with advanced prostatic carcinoma were entered in a phase II trial and were administered fluorouracil (F) 600 mg/m2, on days 1 and 2, doxorubicin (A) 40 mg/m2, on day 1, and cisplatin (P) 90 mg/m2, on day 1, every month. The response was evaluated after three cycles of chemotherapy according to National(More)
Between January 1, 1983 and December 31, 1984, 18 patients with advanced transitional cell carcinoma of the urothelium were treated in a Phase II trial with doxorubicin 45 mg/sqm plus cisplatin 90/mg/sqm/day every four weeks. 17 patients were evaluable for response. There were: 4 partial responses (24% of response objective effects, 95% confidence limits(More)
18 relapses of non seminomatous germ cell cancer of the testis are studied, among a group of 112 patients treated from 1974 to 1978, of which 90 are in complete remission. The study of these cases shows the bad prognosis value of yolk sac tumor component at histological examination. Relapses are more frequent in the stages with lymph node involvement(More)